Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Entecavir - Bristol-Myers Squibb

Drug Profile

Entecavir - Bristol-Myers Squibb

Alternative Names: Baraclude; BMS-200475; SQ 34676

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antivirals; Cyclopentanes; Hypoxanthines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors; RNA-directed DNA polymerase inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis B
  • Discontinued Herpesvirus infections

Most Recent Events

  • 03 Apr 2018 Phase III development is ongoing in South Korea for Hepatitis B (In children, In adolescents) (PO) (NCT01079806)
  • 03 Apr 2018 Bristol-Myers Squibb completes a phase III trial for Hepatitis B (In children, In adolescents) in USA, Argentina, Belgium, Brazil, Canada, Germany, Greece, India, Israel, South Korea, Poland, Romania, Russia, Taiwan and United Kingdom (PO, Tablet, Liquid) (NCT01079806)
  • 04 Sep 2017 Bristol-Myers Squibb completes a phase I/II trial in Hepatitis B (In children, In adolescents) in USA, United Kingdom, Argentina, Belgium, Brazil, Canada, South Korea and Taiwan (PO) (NCT00423891)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top